Montelukast for Children From 2 To 5 Years Accord Healthcare (Montelukast)

Montelukast acts on the leukotriene pathway to control chronic respiratory allergic conditions in pediatric patients.

• Asthma: reduces the frequency of wheezing, coughing and nighttime symptoms, helping to prevent exacerbations.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergies.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and C4 from binding. This inhibition reduces bronchoconstriction, vascular permeability, and inflammatory cell recruitment in the airways, thereby improving respiratory function and decreasing allergic inflammation.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate intensity.
• Abdominal pain: occasional discomfort or cramps.
• Cough: transient irritation of the throat.
• Sore throat: mild irritation without fever.
• Upper respiratory infection: mild cold‑like symptoms.
• Fever: low‑grade temperature elevation.

Serious or Rare Side Effects

• Allergic reactions: rash, angioedema or anaphylaxis.
• Mood changes: depression, anxiety or suicidal thoughts.
• Hepatic enzyme elevation: abnormal liver function tests.
• Neutropenia: reduced white blood cell count.
• Severe bronchospasm: paradoxical worsening of breathing.

When prescribing Montelukast for young children, several safety considerations should be observed.

• Age restriction: use only in children aged 2‑5 years as directed by a healthcare professional.
• Hepatic impairment: exercise caution and monitor liver function in children with known liver disease.
• Behavioral monitoring: observe for mood alterations or suicidal ideation, especially during the first weeks of therapy.
• Concomitant medications: review all current drugs for potential interactions before initiating therapy.
• Pregnancy and lactation: safety data are limited; use only if the benefit outweighs the potential risk.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Phenobarbital: induces hepatic enzymes, reducing Montelukast plasma levels.
• Rifampin: strong enzyme inducer that may decrease therapeutic effect.
• Ketoconazole: potent CYP3A4 inhibitor that can increase Montelukast exposure.
• Other leukotriene modifiers (e.g., zafirlukast): concurrent use may increase risk of adverse reactions.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of anticoagulant effect; monitor INR.
• Oral contraceptives: may experience reduced efficacy; advise additional contraception.
• Theophylline: monitor for increased theophylline concentrations.
• Beta‑agonists: assess for additive bronchodilator effects.